With the completion of the acquisition, Marksans will start operating at the acquired facility.

Marksans Pharma completes the acquisition from Tevapharm India

Tata Elxsi’s trend is down, with supports at ₹5,790 and ₹5,630. Tata Consumer Products has a long-term bullish trend, with a range between ₹695 and ₹760. Marksans Pharma has a bullish outlook for the short- and medium-term, with supports at ₹62 and ₹57 and resistance at ₹90.

Profit Protection Strategy: Tata Elxsi and Tata Consumer Products Under the Spotlight

Broker’s Call: Marksans Pharma (Buy)

Management guided for revenue of Rs 1800 crore, gross margin of 50-51% and Ebitda margin of ~17% in FY23.

Marksans Pharma - With Focus On Backward Integration, Operating Margin Is Expected To Improve: HDFC Securities

Famotidine tablets are bioequivalent to the reference listed drug Pepcid AC tablets, a registered trademark of Johnson & Johnson Consumer Inc, which has sales of over $200 million in the US market.

Marksans Pharma climbs 2% after USFDA approval for Famotidine tablets

Marksans Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic version of Famotidine tablets indicated for the treatment of acid indigestion and heartburn.

Marksans Pharma gets USFDA nod for generic version of Famotidine tablets

Marksans Pharma gets final USFDA nod for generic version of Famotidine tablets

Marksans Pharma said that the UK MHRA has granted market authorisation to the company’s wholly owned subsidiary Relonchem for Fluoxetine 20mg/5ml oral solution.

Marksans Pharma gets UK MHRA approval for Fluoxetine oral solution

Marksans Pharma rose 2.80% to Rs 67.90 after the company said it raised Rs 372.40 crore in equity via conversion of warrants issued to OrbiMed and the promoter.

Marksans Pharma jumps on raising funds via conversion of warrants

Tata Motors can face stiff resistance near its 200 DMA which is also coinciding with falling trendline on the daily chart that is placed around Rs 427-430 zone

Tata Motors, Marksans Pharma, Voda Idea: Trading strategies for the 3 stocks

Marksans Pharma share price: There were 23,46,630 buy orders on BSE, against sell orders of 1,17,759 shares. On NSE, 1.33 crore shares traded for a value of Rs 87.33 crore.

Marksans Pharma shares jump 8% to hit 52-week high today; here’s why

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.